日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

Quizartinib治疗新诊断的FLT3内部串联重复阴性AML:一项随机、双盲、安慰剂对照的II期QUIWI研究

Montesinos, Pau; Rodríguez-Veiga, Rebeca; Bergua, Juan Miguel; Algarra Algarra, Jesús Lorenzo; Botella, Carmen; Rodríguez-Arbolí, Eduardo; Bernal, Teresa; Tormo, Mar; Calbacho, Maria; Salamero, Olga; Serrano, Josefina; Noriega, Victor; López-López, Juan Antonio; Vives, Susana; López-Lorenzo, Jose Luis; Colorado, Mercedes; Vidriales, Maria-Belén; García Boyero, Raimundo; Olave, Maria Teresa; Herrera Puente, Pilar; Arce, Olga; Barrios, Manuel; Jose Sayas, Maria; Polo, Marta; Gómez-Roncero, Maria Isabel; Barragán, Eva; Ayala, Rosa; Chillón, Carmen; Calasanz, Maria José; Paiva, Bruno; Boluda, Blanca; Casas-Avilés, Ignacio; Lloret-Madrid, Pilar; Sánchez, Maria-José; Rodríguez-Medina, Carlos; Cuevas, Laida; Raposo-Puglia, José Ángel; Mateos, M Carmen; Olivares, Matxalen; Martínez-Chamorro, Carmen; Alonso, Natalia; Suárez, Sandra; Sánchez-Vadillo, Irene; Solé Rodríguez, María; González, Bernardo Javier; Martínez-Francés, Antonio; Cuello, Rebeca; Fernández, Alfonso; Martínez-Cuadrón, David; Labrador, Jorge

Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML

多选择性 RAS(ON) 抑制剂靶向致癌 RAS,并克服急性髓系白血病 (AML) 中 RAS 介导的对 FLT3 抑制剂和 BCL2 抑制剂的耐药性。

Popescu, Bogdan; Jones, Matthew F; Piao, Madison; Tran, Elaine; Koh, Andrew; Lomeli, Isabelle; Peretz, Cheryl A C; Murad, Natalia; Abelson, Sydney; Morales, Carolina; Rivera, Jose M; Batingana, Alexa Rane; D'Souza, Jeevitha; Pikman, Yana; Cheng, Michael L; Logan, Aaron C; Huang, Benjamin J; Stieglitz, Elliot; Smith, Catherine C

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia

骨髓增生异常相关基因突变对FLT3-ITD突变型急性髓系白血病预后的影响

Mecklenbrauck, Rabea; Villaverde Ramiro, Angela; Sträng, Eric; Gabdoulline, Razif; Martinez Elicegui, Javier; Sobas, Marta; Pleyer, Lisa; Turki, Amin; Voso, Maria Teresa; Benner, Axel; Hernández-Sánchez, Alberto; Tettero, Jesse M; Tur Gimenez, Laura; Metzeler, Klaus H; Oñate, Guadalupe; Lehmann, Sören; Huntly, Brian Jp; Thomas, Ian; Thol, Felicitas R; Heidel, Florian H; Valk, Peter Jm; Döhner, Konstanze; Haferlach, Torsten; Mills, Kenneth I; Döhner, Hartmut; Castellani, Gastone; Ossenkoppele, Gert J; Hernández-Rivas, Jesus María; Bullinger, Lars; Heuser, Michael

Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data

共存的FLT3突变在接受强化治疗的急性髓系白血病分子亚组中的预后影响:来自真实世界基因组数据的启示

Chang, Yu-Sung; Tien, Feng-Ming; Wang, Yu-Wen; Yao, Chi-Yuan; Tsai, Xavier Cheng-Hong; Ni, Sao-Chih; Lo, Min-Yen; Lee, Wan-Hsuan; Lin, Chien-Chin; Kuo, Yuan-Yeh; Peng, Yen-Ling; Tseng, Mei-Hsuan; Ko, Bor-Sheng; Yao, Ming; Tien, Hwei-Fang; Hou, Hsin-An; Chou, Wen-Chien

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

吉瑞替尼在复发/难治性FLT3突变急性髓系白血病二线治疗后的疗效:一项纳入171例患者的真实世界多中心研究

Molica, Matteo; Miralles, Gema; Dillon, Richard; Annunziata, Mario; Basheer, Faisal; Bergua, Juan M; Calmet, Ferran Vall-Llovera; Campbell, Victoria; Cetin, Denis; Cimino, Gaetano; Ciotti, Giulia; Corbingi, Andrea; De Fazio, Laura; Erol, Hasim Atakan; Federico, Vincenzo; Gil, Cristina; Mutlu, Yasa Gul; Malcorra, Amaia Balerdi; Mariani, Sabrina; Mazzone, Carla; Mulè, Antonino; Musuraca, Gerardo; Khan, Anjum; Norata, Mariana; O'Nions, Jenny; Palumbo, Fanny Erika; Papayannidis, Cristina; Piccioni, Anna Lina; Rubio, Maria Teresa Olave; Sanchez-Tovar, Jackeline; Serin, Istemi; Serrao, Alessandra; Sevindik, Omur Gokmen; Sucato, Giuseppe; Urbano, Marina Aurora; Vetro, Calogero; Vives, Susana; Rossi, Marco; Martelli, Maria Paola; Montesinos, Pau; Othman, Jad; Perrone, Salvatore

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

一项针对≥60岁FLT3突变型急性髓系白血病(AML)成人患者的FILO-DATAML-PETHEMA真实世界研究:强化化疗联合或不联合米哚妥林治疗的疗效评价

Aspas Requena, Gaspar; Montesinos, Pau; Bérard, Emilie; Bertoli, Sarah; Rodríguez-Veiga, Rebeca; Simand, Celestine; Torres, Laura; Peterlin, Pierre; Tormo, Mar; Birsen, Rudy; Bergua-Burgues, Juan Miguel; Tavernier, Emmanuelle; Bernal Del Castillo, Teresa; Carré, Martin; Gil, Cristina; Contejean, Adrien; Rodríguez-Arbolí, Eduardo; Orvain, Corentin; Rodríguez-Medina, Carlos; Veronese, Lauren; Sayas Lloris, Maria Jose; Delabesse, Eric; Serrano, Josefina; Mineur, Ariane; García-Fortes, María; Guieze, Romain; Amigo, Maria Luz; Pigneux, Arnaud; Algarra Algarra, Lorenzo; Recher, Christian; Dumas, Pierre-Yves; Martínez-Cuadrón, David

Day + 30 detection of minimal residual FLT3-ITD by high-sensitivity PCR-NGS predicts relapse risk and guides post-transplant maintenance in AML

移植后第30天通过高灵敏度PCR-NGS检测微小残留FLT3-ITD可预测复发风险并指导AML移植后的维持治疗。

Jiang, Shan; Feng, Dan; Wan, Li; Yang, Nan; Ma, Jiao; Cao, Jiaxin; Pan, Pan; Zheng, Yawei; Cao, Yigeng; Cao, Wenbin; Liang, Chen; Chen, Xin; Zhang, Rongli; Ma, Qiaoling; Wei, Jialin; Zhai, Weihua; Yang, Donglin; He, Yi; Feng, Sizhou; Han, Mingzhe; Yao, Yao; Pang, Aiming; Jiang, Erlie

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML

FLT3-SYK抑制剂与伊沙佐米联合用药可影响急性髓系白血病中HOXA和β-catenin、SQSTM1和NRF2介导的氧化应激调控。

Pasupuleti, Santhosh Kumar; Rangaraju, Sravanti; Layer, Justin; Padam, Kanaka Sai Ram; Cripe, Larry D; Sayar, Hamid; Sargent, Katie J; Weisenbach, Jill; Konig, Heiko; Salman, Huda; Ramdas, Baskar; Palam, Lakshmi Reddy; Mayo, Lindsey D; Khan, Irum; Davé, Utpal P; Boswell, H Scott; Kapur, Reuben

All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the CON

所有患有急性髓系白血病且伴有FLT3-ITD突变的患者都应在首次缓解期接受移植。即使在酪氨酸激酶抑制剂时代也是如此吗?——反对

Russell, Nigel H; Lewis, Katie D

All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the PRO

所有患有FLT3-ITD突变的急性髓系白血病(AML)患者都应在首次缓解期接受移植。即使在酪氨酸激酶抑制剂时代也是如此吗?——PRO

Kayser, Sabine; Schlenk, Richard F